Pharmacotherapy of Autism and Related Disorders

被引：5

作者：

Blankenship, Kelly ^{[1
,2
]}

Erickson, Craig A. ^{[1
,2
]}

McDougle, Christopher J. ^{[1
,2
]}

机构：

[1] Indiana Univ, Dept Psychiat, Sch Med, Indianapolis, IN 46202 USA

[2] James Whitcomb Riley Hosp Children, Christian Sarkine Autism Treatment Ctr, Indianapolis, IN 46202 USA

来源：

PSYCHIATRIC ANNALS | 2010年 / 40卷 / 04期

关键词：

PERVASIVE DEVELOPMENTAL DISORDERS; DOUBLE-BLIND; RETROSPECTIVE ANALYSIS; SPECTRUM DISORDERS; CHILDREN; ADOLESCENTS; HYPERACTIVITY; ATOMOXETINE; SYMPTOMS; ARIPIPRAZOLE;

D O I：

10.3928/00485713-20100330-06

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Public awareness of pervasive developmental disorders (PDDs), including autistic disorder (autism), has been increasing. In parallel, results from research directed toward pharmacologic treatment of interfering symptoms associated with PDDs has escalated. This review will focus on controlled drug studies performed to treat the interfering symptoms of PDDs. These include hyperactivity/inattention, repetitive and stereotypic behavior, irritability (aggression, self-injury, severe tantrums) and core social impairment. A priority is placed on randomized, placebo-controlled trials when available. The side effects of the medications in this population are also discussed.

引用

页码：203 / 209

页数：7

共 40 条

[1]

Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266

[2] STIMULANT DRUG EFFECTS IN DEVELOPMENTAL DISORDERS AND HYPERACTIVITY - TOWARD A RESOLUTION OF DISPARATE FINDINGS [J].